SecSonar.com

BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Corp. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

BioNexus Gene Lab Corp. (BGLC) is a Medical - Diagnostics & Research company based in MY with a market capitalization of $4.4M. Revenue declined 21.9% year-over-year and free cash flow was negative at -$1.9M. This page tracks BGLC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

MY · 30 employees · IPO Jan 8, 2021

Valuation

Valuation & price

$2.10 · as of May 26, 2026 · -70.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

0.51

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$6.93$4.44$1.95Jul 25Dec 25Jul 26Jul 7, 25$5.93Jul 9, 25$5.82Jul 11, 25$5.09Jul 15, 25$3.75Jul 17, 25$6.63Jul 21, 25$4.94Jul 23, 25$5.15Jul 25, 25$4.90Jul 29, 25$4.46Jul 31, 25$6.93Aug 4, 25$6.64Aug 6, 25$5.66Aug 11, 25$5.44Aug 13, 25$5.57Aug 15, 25$5.34Aug 19, 25$5.32Aug 21, 25$5.72Aug 25, 25$5.64Aug 27, 25$5.59Aug 29, 25$5.68Sep 3, 25$5.66Sep 5, 25$5.04Sep 9, 25$4.41Sep 11, 25$4.30Sep 16, 25$5.22Sep 18, 25$5.70Sep 22, 25$5.49Sep 24, 25$5.69Sep 26, 25$5.65Sep 30, 25$5.47Oct 2, 25$5.36Oct 6, 25$5.26Oct 8, 25$5.53Oct 10, 25$5.19Oct 14, 25$5.05Oct 16, 25$5.16Oct 21, 25$5.20Oct 23, 25$5.19Oct 27, 25$5.06Oct 29, 25$5.12Oct 31, 25$5.42Nov 4, 25$5.31Nov 6, 25$5.22Nov 10, 25$5.24Nov 12, 25$4.84Nov 14, 25$4.53Nov 18, 25$4.81Nov 20, 25$4.35Nov 25, 25$4.32Nov 28, 25$4.54Dec 2, 25$4.35Dec 4, 25$4.33Dec 8, 25$4.28Dec 10, 25$4.34Dec 12, 25$4.15Dec 16, 25$4.12Dec 18, 25$4.13Dec 22, 25$4.10Dec 24, 25$4.15Dec 29, 25$4.09Jan 2, 26$3.94Jan 6, 26$3.86Jan 8, 26$3.90Jan 12, 26$3.75Jan 14, 26$3.76Jan 16, 26$3.64Jan 21, 26$3.07Jan 23, 26$3.12Jan 27, 26$2.72Jan 29, 26$2.65Feb 2, 26$2.83Feb 4, 26$2.35Feb 9, 26$2.02Feb 11, 26$1.95Feb 13, 26$2.14Feb 18, 26$2.28Feb 20, 26$2.43Feb 24, 26$2.53Feb 26, 26$2.50Mar 2, 26$2.65Mar 4, 26$2.62Mar 6, 26$2.50Mar 10, 26$2.18Mar 12, 26$2.23Mar 17, 26$2.54Mar 19, 26$2.56Mar 23, 26$2.65Mar 25, 26$2.49Mar 27, 26$2.35Mar 31, 26$2.14Apr 2, 26$2.21Apr 7, 26$2.30Apr 9, 26$2.25Apr 13, 26$2.26Apr 15, 26$2.18Apr 17, 26$2.20Apr 22, 26$2.26Apr 24, 26$2.22Apr 28, 26$2.07Apr 30, 26$2.10May 4, 26$2.04May 6, 26$2.00May 8, 26$2.06May 12, 26$2.02May 14, 26$1.98May 18, 26$2.09May 20, 26$2.09May 22, 26$2.02May 28, 26$2.40Jun 1, 26$2.24Jun 3, 26$2.28Jun 5, 26$2.20Jun 9, 26$2.17Jun 11, 26$2.11Jun 15, 26$2.50Jun 17, 26$2.52Jun 22, 26$2.42Jun 24, 26$2.10Jun 26, 26$2.07Jul 2, 26$2.03
$1.9452-week range$7.18
Loading valuation history…

Fundamentals

Key fundamentals

$4.4M

Market cap

-21.9%

Revenue growth (YoY)

14.6%

Gross margin

-$1.9M

Free cash flow (USD)

-$2.2M

Net debt

Net cash position

4.2%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$107.7KFY 2018$212.3KFY 2019$127.0KFY 2020$11.4MFY 2021$13.4MFY 2022$10.9MFY 2023$9.8MFY 2024$9.5MFY 2025$7.4M
$0$7.4M

Free cash flow by year

2016 → 2025

FY 2016$-835.00FY 2017$42.4KFY 2018$-313.7KFY 2019$-230.1KFY 2020$131.1KFY 2021$6.0KFY 2022$497.7KFY 2023$-1.9MFY 2024$-2.5MFY 2025$-1.9M
-$835-$1.9M

Gross margin by year

2021 → 2025

FY 202116.4%FY 202211.5%FY 202313.6%FY 202413.6%FY 202514.6%
16.4%14.6%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: May 15, 2026 (EPS $-0.23)

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventPress Release IssuedJun 5, 2026Filing
  • Quarterly report10-Q FiledMay 15, 2026Filing
  • Annual report10-K FiledApr 14, 2026Filing

Questions

Frequently asked questions

What is BioNexus Gene Lab Corp.'s market cap?

BioNexus Gene Lab Corp. (BGLC) has a market capitalization of $4.4M.

What is BGLC's P/E ratio?

A meaningful P/E ratio is not available for BGLC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is BGLC's price-to-book (P/B) ratio?

BGLC trades at 0.51 times book value per share.

When did BioNexus Gene Lab Corp. last report earnings?

BGLC last reported earnings on May 15, 2026; the next date is not yet scheduled.

Are insiders buying BGLC stock?

SEC Form 4 filings show no open-market insider buys at BioNexus Gene Lab Corp. in the last 90 days (0 sells).

Same arena

Related companies in Medical - Diagnostics & Research

INBS

Intelligent Bio Solutions Inc.

$1.6M

TRIB

Trinity Biotech plc

$7.4M

BIAF

bioAffinity Technologies, Inc.

$7.7M

ISPC

iSpecimen Inc.

$437K

NOTV

Inotiv, Inc.

$9.8M

VNRX

VolitionRx Limited

$15.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.